552 related articles for article (PubMed ID: 29180535)
1. Radiotherapy and CTLA-4 Blockade Shape the TCR Repertoire of Tumor-Infiltrating T Cells.
Rudqvist NP; Pilones KA; Lhuillier C; Wennerberg E; Sidhom JW; Emerson RO; Robins HS; Schneck J; Formenti SC; Demaria S
Cancer Immunol Res; 2018 Feb; 6(2):139-150. PubMed ID: 29180535
[TBL] [Abstract][Full Text] [Related]
2. Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts.
Woolaver RA; Wang X; Krinsky AL; Waschke BC; Chen SMY; Popolizio V; Nicklawsky AG; Gao D; Chen Z; Jimeno A; Wang XJ; Wang JH
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33414263
[TBL] [Abstract][Full Text] [Related]
3. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
[TBL] [Abstract][Full Text] [Related]
4. Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy.
Page DB; Yuan J; Redmond D; Wen YH; Durack JC; Emerson R; Solomon S; Dong Z; Wong P; Comstock C; Diab A; Sung J; Maybody M; Morris E; Brogi E; Morrow M; Sacchini V; Elemento O; Robins H; Patil S; Allison JP; Wolchok JD; Hudis C; Norton L; McArthur HL
Cancer Immunol Res; 2016 Oct; 4(10):835-844. PubMed ID: 27587469
[TBL] [Abstract][Full Text] [Related]
5. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.
Duraiswamy J; Kaluza KM; Freeman GJ; Coukos G
Cancer Res; 2013 Jun; 73(12):3591-603. PubMed ID: 23633484
[TBL] [Abstract][Full Text] [Related]
6. TCR repertoire intratumor heterogeneity of CD4
Zhang C; Ding H; Huang H; Palashati H; Miao Y; Xiong H; Lu Z
Int J Cancer; 2019 Feb; 144(4):818-827. PubMed ID: 30151844
[TBL] [Abstract][Full Text] [Related]
7. Expansion of Tumor-reactive T Cells From Patients With Pancreatic Cancer.
Meng Q; Liu Z; Rangelova E; Poiret T; Ambati A; Rane L; Xie S; Verbeke C; Dodoo E; Del Chiaro M; Löhr M; Segersvärd R; Maeurer MJ
J Immunother; 2016; 39(2):81-9. PubMed ID: 26849077
[TBL] [Abstract][Full Text] [Related]
8. Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity.
Leshem Y; O'Brien J; Liu X; Bera TK; Terabe M; Berzofsky JA; Bossenmaier B; Niederfellner G; Tai CH; Reiter Y; Pastan I
Cancer Immunol Res; 2017 Aug; 5(8):685-694. PubMed ID: 28674083
[TBL] [Abstract][Full Text] [Related]
9. Clonality of CD4
Arakawa A; Vollmer S; Tietze J; Galinski A; Heppt MV; Bürdek M; Berking C; Prinz JC
Front Immunol; 2019; 10():1336. PubMed ID: 31275310
[TBL] [Abstract][Full Text] [Related]
10. TCR Repertoire Analysis Reveals Mobilization of Novel CD8
Aoki H; Ueha S; Shichino S; Ogiwara H; Hashimoto SI; Kakimi K; Ito S; Matsushima K
Front Immunol; 2018; 9():3185. PubMed ID: 30733724
[TBL] [Abstract][Full Text] [Related]
11. CTLA-4 blockade boosts the expansion of tumor-reactive CD8
Friese C; Harbst K; Borch TH; Westergaard MCW; Pedersen M; Kverneland A; Jönsson G; Donia M; Svane IM; Met Ö
Sci Rep; 2020 Mar; 10(1):3914. PubMed ID: 32127601
[TBL] [Abstract][Full Text] [Related]
12. TCR function analysis using a novel system reveals the multiple unconventional tumor-reactive T cells in human breast cancer-infiltrating lymphocytes.
Yamaguchi S; Hamana H; Shitaoka K; Sukegawa K; Nagata T; Hayee A; Kobayashi E; Ozawa T; Fujii T; Muraguchi A; Tobe K; Kishi H
Eur J Immunol; 2021 Sep; 51(9):2306-2316. PubMed ID: 34171120
[TBL] [Abstract][Full Text] [Related]
13. Relationship between T cell receptor clonotype and PD-1 expression of tumor-infiltrating lymphocytes in colorectal cancer.
Sukegawa K; Shitaoka K; Hamana H; Kobayashi E; Miyahara Y; Fujii K; Tsuda K; Saeki S; Nagata T; Ozawa T; Saito S; Fujii T; Muraguchi A; Shiku H; Kishi H
Eur J Immunol; 2020 Oct; 50(10):1580-1590. PubMed ID: 32441316
[TBL] [Abstract][Full Text] [Related]
14. The T-cell receptor repertoire of tumor-infiltrating regulatory T lymphocytes is skewed toward public sequences.
Sainz-Perez A; Lim A; Lemercier B; Leclerc C
Cancer Res; 2012 Jul; 72(14):3557-69. PubMed ID: 22573714
[TBL] [Abstract][Full Text] [Related]
15. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies.
Wei SC; Anang NAS; Sharma R; Andrews MC; Reuben A; Levine JH; Cogdill AP; Mancuso JJ; Wargo JA; Pe'er D; Allison JP
Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22699-22709. PubMed ID: 31636208
[TBL] [Abstract][Full Text] [Related]
16. Identification of Tumoricidal TCRs from Tumor-Infiltrating Lymphocytes by Single-Cell Analysis.
Shitaoka K; Hamana H; Kishi H; Hayakawa Y; Kobayashi E; Sukegawa K; Piao X; Lyu F; Nagata T; Sugiyama D; Nishikawa H; Tanemura A; Katayama I; Murahashi M; Takamatsu Y; Tani K; Ozawa T; Muraguchi A
Cancer Immunol Res; 2018 Apr; 6(4):378-388. PubMed ID: 29475880
[TBL] [Abstract][Full Text] [Related]
17. Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer.
Hu ZI; Ho AY; McArthur HL
Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):153-164. PubMed ID: 28816141
[TBL] [Abstract][Full Text] [Related]
18. Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects.
Ruocco MG; Pilones KA; Kawashima N; Cammer M; Huang J; Babb JS; Liu M; Formenti SC; Dustin ML; Demaria S
J Clin Invest; 2012 Oct; 122(10):3718-30. PubMed ID: 22945631
[TBL] [Abstract][Full Text] [Related]
19. Tumor-Infiltrating Merkel Cell Polyomavirus-Specific T Cells Are Diverse and Associated with Improved Patient Survival.
Miller NJ; Church CD; Dong L; Crispin D; Fitzgibbon MP; Lachance K; Jing L; Shinohara M; Gavvovidis I; Willimsky G; McIntosh M; Blankenstein T; Koelle DM; Nghiem P
Cancer Immunol Res; 2017 Feb; 5(2):137-147. PubMed ID: 28093446
[TBL] [Abstract][Full Text] [Related]
20. Divergent outcomes of anti-PD-L1 treatment coupled with host-intrinsic differences in TCR repertoire and distinct T cell activation states in responding versus non-responding tumors.
John J; Woolaver RA; Popolizio V; Chen SMY; Ge H; Krinsky AL; Vashisht M; Kramer Y; Chen Z; Wang JH
Front Immunol; 2022; 13():992630. PubMed ID: 36330507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
